Clinical trial
Effect of Rituximab on Immunological Recall Response to Specific Antigens in the…
NCT00090038 · Biogen, Industry · Completed
Key facts
| NCT number | NCT00090038 |
|---|---|
| Title | Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma |
| Official title | A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens |
| Lead sponsor | Biogen, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | rituximab |
| Enrollment | 168 |
| Start date | Oct 1, 2003 |
| Primary completion | Jun 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Aug 24, 2004 |
| Last update posted | Oct 20, 2009 |
| Countries | Austria, Czechia, France, Germany, Lithuania, Romania, Russia, Sweden, Turkey (Türkiye), United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: